InspireMD Inc.
News
NSPR Stock Earnings: InspireMD Misses EPS, Misses Revenue for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nNSPR stock results show that InspireMD missed analyst estimates for earnings per share and missed on revenue for the second quarter of...\n more…
InspireMD, Inc. (NSPR) Reports Q2 Loss, Misses Revenue Estimates
Zacks Investment Research InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.24 per share a year ago. These figures are...\n more…
InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update
Globe Newswire - Announced positive outcomes from the C-GUARDIANS IDE clinical trial of the CGuard Prime carotid stent system demonstrating a one-year primary endpoint event rate of 1.95%, the lowest for any...\n more…
InspireMD Q2 2024 Earnings Preview
Seeking Alpha - Israel Stocks InspireMD Q2 2024 Earnings Preview...\n more…
InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th
Globe Newswire -Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, and MIAMI, July 30, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention...\n more…
